Floatz logo

Desmopressin

Sickle Cell Disease

Montefiore Medical Centerprotein_peptidePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

133 Active assets in the Sickle Cell Disease cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
Nivestim
St. Jude Children's Research Hospital
Phase 4BB
Magnesium Metallicum
Medical College of Wisconsin
Phase 3BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB

View all 50 →

Same molecule, other indications

Desmopressin is also rated in:

hemophilia AActive
BB
Indicative · Phase 4
66 / 100
View asset →
nocturnal enuresisDormant
BB
Indicative · Phase 4
65 / 100
View asset →
stroke disorderDormant
BB
Indicative · Phase 2
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →